SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1757Parking... REGN Dupilumab FeNO in 2b 12 wk interim (FeNO as marker of pulmonaryBiotech Jim-5/18/2015
1756Parking... REGN Dupilumab FEV1 in 2b 12 wk interim [graphic]Biotech Jim-5/18/2015
1755Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in AsthmaBiotech Jim-5/18/2015
1754Regeneron lobbying for its database to be the linchpin of Obama's Precision Biotech Jim-5/18/2015
1753They mentioned combining 1033 in their CC: Overall, the drug was well toleratedFelix B-5/12/2015
1752They do not need to combine 1033 (for sarcopenia), it is PD1-antibody (REGN 281Miljenko Zuanic-5/8/2015
1751Surprised 1033 is going so well, I believe Novartis ab is decision date is due Felix B-5/8/2015
17501Q: finance.yahoo.com So far spending is under control (or, so-so, it could be Miljenko Zuanic15/7/2015
1749Eylea (ROW) sales for 1Q v 4Q (per Bayer) are E253 v 219, or 15% increase. IF thMiljenko Zuanic-4/30/2015
1748Correction: Price target raised to $533 from prior target of $490.Biotech Jim-4/29/2015
1747From RBC Capital, this morning's report, with a price target of $490. Thx DBiotech Jim-4/29/2015
1746Sarcopenia and doping, I never though about that way. You have a point!Miljenko Zuanic-4/29/2015
1745I do know that George Y is bullish on this target and Ab. His early work was inBiotech Jim-4/29/2015
1744Thanks Jim. It seams, based on recent clinical development, that 1033 is moving Miljenko Zuanic-4/29/2015
1743FDA AdComm Panels for PCSK9 antibody therapies on June 9~10th, REGN/SNY on the 9Biotech Jim-4/29/2015
1742Update on REGN clinical trial for new programs: 1. REGN2176-3 for AMD, Miljenko Zuanic-4/17/2015
1741SERONJA ne moze a da ne prodaje! investor.regeneron.comMiljenko Zuanic-3/25/2015
1740They were ischemic stroke, so somehow blood-plug develop? It was not that visiblMiljenko Zuanic-3/19/2015
1739Endothelial cells on the CNS blood vasculature have "tight junctions" Biotech Jim-3/19/2015
1738It is hard to find any correlation, particular due to facts that mAb (or large pMiljenko Zuanic-3/19/2015
1737I saw that Miljenko, and was surprised. I have no particular insight into the sBiotech Jim-3/18/2015
173611 cases of STROKE in Alirocumab arm, only two in placebo (statin only)???!!! AnMiljenko Zuanic-3/17/2015
1735REGN 8K filing: investor.regeneron.com Efficacy and safety of alirocumab 150 mBiotech Jim-3/16/2015
1734Increasing trial size midstream incurs an alpha hit, so it’s not a clear-cut decDewDiligence_on_SI-3/16/2015
1733Sanofi CONFIDENCE or STUPIDITY???? Based on observed event rate per year in &qMiljenko Zuanic-3/15/2015
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News